Sugi Predict

Sugi Predict / Compounds / SCHEMBL2154073

SCHEMBL2154073

SCHEMBL2154073

COc1cc(F)ccc1-c1c(Cl)sc2c1C(=O)C(C)(c1ccccc1)C(=O)N2

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 12/20 0.47
▸ MAPT P10636 2/20 0.39
▸ STK10 O94804 1/20 0.36
▸ SLK Q9H2G2 1/20 0.36
▸ CTSA P10619 1/20 0.35
▸ DRD1 P21728 2/20 0.35
▸ HTR1A P08908 1/20 0.35
▸ HTR2A P28223 1/20 0.35
▸ HTR7 P34969 1/20 0.35
▸ MMP2 P08253 1/20 0.34
▸ MMP9 P14780 1/20 0.34
▸ GRIN1 Q05586 1/20 0.33
▸ GRIN2B Q13224 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ NR3C1 P04150 1/20 0.33
▸ PGR P06401 1/20 0.33
▸ NR3C2 P08235 1/20 0.33
▸ AR P10275 1/20 0.33
▸ SLC6A9 P48067 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2154394 0.89 HTR6 (0.50) HTR6MAPTSTK10SLKDRD1
SCHEMBL14718107 0.89 STK10 (0.44) HTR6MAPTSTK10SLKDRD1
SCHEMBL2153898 0.89 HTR6 (0.42) HTR6MAPTSTK10SLKSLC6A9
SCHEMBL2153524 0.85 HTR6 (0.51) HTR6MAPTCTSADRD1HTR1A
SCHEMBL13570752 0.84 HTR6 (0.39) HTR6MAPTSTK10SLKCTSA
SCHEMBL2154031 0.83 HTR6 (0.43) HTR6MAPTDRD1HTR1AHTR2A
SCHEMBL2153158 0.82 HTR6 (0.50) HTR6MAPTSTK10SLKMMP2
SCHEMBL2153946 0.82 HTR6 (0.42) HTR6STK10SLK
SCHEMBL14718112 0.82 HTR6 (0.48) HTR6
SCHEMBL2153684 0.82 HTR6 (0.43) HTR6MAPTDRD1HTR1AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2519527-B1 THIENO[2,3-B]PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF POXEL (FR) 2013-12-18 — — EP claimed
US-20130053401-A1 THIENO [2,3-B] PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF POXEL (FR) 2013-02-28 — — US claimed
EP-2519527-A1 THIENO [2,3-B]PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF Poxel (FR) 2012-11-07 — — EP claimed
WO-2011080277-A1 THIENO [2,3-B] PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF POXEL (FR) 2011-07-07 — — WO claimed
US-9365584-B2 Thieno [2,3-B] pyridinedione activators of AMPK and therapeutic uses thereof POXEL (FR) 2016-06-14 — — US disclosed
EP-2519527-B1 THIENO[2,3-B]PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF POXEL (FR) 2013-12-18 — — EP disclosed
US-20130053401-A1 THIENO [2,3-B] PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF POXEL (FR) 2013-02-28 — — US disclosed
EP-2519527-A1 THIENO [2,3-B]PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF Poxel (FR) 2012-11-07 — — EP disclosed
WO-2011080277-A1 THIENO [2,3-B] PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF POXEL (FR) 2011-07-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053401-A1 THIENO [2,3-B] PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF PRKAB1, PRKAG1, PRKAB2 HTR6 2378/4885MAPT 3687/4885STK10 89/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.